You are here
ORCHID: Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease
Effective therapies for COVID-19 are urgently needed. The PETAL Network is responding to the COVID-19 crisis and redirecting effort to develop and deploy COVID-19 trials. The first is the ORCHID Trial. Hydroxychloroquine is an antimicrobial agent with immunomodulatory and antiviral properties that has demonstrated in vitro activity against SARS-CoV-2, the virus that causes COVID-19. Preliminary reports suggest potential efficacy in small human studies. Clinical trial data are needed to determine whether hydroxychloroquine is effective in treating COVID-19.
ORCHID is a blinded, multicenter, placebo-controlled randomized clinical trial of oral doses of Hydroxychloroquine as compared to a matching placebo to treat patients hospitalized with COVID-19 illness (by positive test or presumed positive based on protocol specific criteria).
This trial was launched in the first week of April and is actively enrolling subjects. As so many things in this pandemic are rapidly changing this protocol will be updated as needed to address relevant changes.